Markets are signaling something important today. Nvidia's next-generation Rubin AI GPU platform potentially facing production delays is casting a shadow on the AI chip sector, while positive clinical trial data from Biomea Fusion offers a bright spot in the biotech space. This week's picks reflect a blend of caution and optimism as we navigate these crosscurrents.
First, we're watching AVGO closely after its -4.11% dip. The potential delay in Nvidia's Rubin GPU, attributed to HBM4 memory supply constraints, highlights the fragility of the AI supply chain. While AVGO isn't directly mentioned in the delay reports, the interconnectedness of the chip manufacturing ecosystem means that headwinds for one major player can easily impact others. Entry consideration would be around the $315 level, looking for a potential rebound if supply chain issues resolve. Risk factors include continued supply chain disruptions and increased competition in the chip market.
Next, BMEA is on our radar following the presentation of 52-week COVALENT-111 data. The data demonstrates durable icovamenib efficacy and a 24% increase in C-Peptide Index in type 2 diabetes subgroups. This suggests a potentially sustained treatment effect. While still early-stage, these results are encouraging. A potential entry point could be around $1.30, with a stop-loss order placed to manage risk. Key risk factors include the possibility of adverse clinical trial results in later stages and regulatory hurdles.
Finally, we're keeping an eye on TLX. Telix has refiled its NDA for Pixclara, designated as an orphan drug, to address the unmet need for brain cancer imaging in the U.S. The refiling includes additional data requested by the FDA, demonstrating a commitment to meeting regulatory requirements. This could represent a significant advancement in diagnostic capabilities. Monitor for news of FDA acceptance for review, which could act as a catalyst. Risk factors include potential rejection by the FDA.
Keep these levels in mind as you navigate today's session.